Germline genetic testing to predict drug response and toxicity in oncology- Reality or fiction?

by Soh, T.I., Yong, W.P.
Published 2014

Recent progress and clinical importance on pharmacogenetics in cancer therapy

by Soh, T.I.P., Yong, W.P., Innocenti, F.
Published 2014

Targeted therapy at the end of life in advanced cancer patients

by Soh, T.I.P., Yuen, Y.-C., Teo, C., Lim, S.-W., Chan, N., Wong, A.S.C.
Published 2014

Common bile duct obstruction by intraluminal colorectal metastasis without evidence of liver or intraabdominal nodal metastasis

by Soh, T.I.P., Doshi, B.K., Putti, T.C., Ang, B.W.L., Aw, D.C.W., Cheong, W.K., Lee, S.-C., Chuah, B.Y.S.
Published 2014

Conversion Surgery Post-Intraperitoneal Paclitaxel and Systemic Chemotherapy for Gastric Cancer Carcinomatosis Peritonei. Are We Ready?

by Chan D.Y.S., Syn N.L.-X., Yap R., Phua J.N.S., Soh T.I.P., Chee C.E., Nga M.E., Shabbir A., So J.B.Y., Yong W.P.
Published 2018

Phenotyping of UGT1A1 Activity Using Raltegravir Predicts Pharmacokinetics and Toxicity of Irinotecan in FOLFIRI

by Lee L.S.-U., Seng K.-Y., Wang L.-Z., Yong W.-P., Hee K.-H., Soh T.I., Wong A., Cheong P.F., Soong R., Sapari N.S., Soo R., Fan L., Lee S.-C., Goh B.C.
Published 2018

Phase Ib/II randomized, open-label study of doxorubicin and cyclophosphamide with or without low-dose, short-course sunitinib in the pre-operative treatment of breast cancer

by Wong A.L.A., Sundar R., Wang T.-T., Ng T.-C., Zhang B., Tan S.-H., Soh T.I.P., Pang A.S.L., Tan C.-S., Ow S.G.W., Wang L., Mogro J., Ho J., Jeyasekharan A.D., Huang Y., Thng C.-H., Chan C.-W., Hartman M., Iau P., Buhari S.A., Goh B.-C., Lee S.-C.
Published 2020